MGNX EBITDA | MACROGENICS, INC.

MACROGENICS, INC. (MGNX) EBITDA

2026-06-30: Basis Reported; EBITDA -$13.14M*; Operating income -$13.85M; Depreciation and amortization $708.00K*.
2026-03-31: Basis Reported; EBITDA -$31.75M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$10.39M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $20.43M*; Operating income $18.64M; Depreciation and amortization $1.79M*.

Complete source-backed ebitda history.

Available history: 2011-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$13.14M*	-$13.85M	$708.00K*	(m)	(m)	$806.00K*	-$40.75M*	(m)	$38.78M	(m)	$0.00
2026-03-31	Reported	-$31.75M	(m)	(m)	(m)	-152.84%	$344.00K	-$35.81M	(m)	$34.97M	(m)	(m)
2025-12-31	Reported	-$10.39M	(m)	(m)	(m)	-25.21%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$20.43M*	$18.64M	$1.79M*	(m)	(m)	$426.00K*	-$30.19M*	$0.00	$32.71M	(m)	$0.00
2025-06-30	Reported	-$41.32M*	-$43.22M	$1.91M*	(m)	(m)	$715.00K*	-$46.98M*	$0.00	$40.79M	(m)	$105.00K
2025-03-31	Reported	-$40.85M	(m)	(m)	(m)	-309.68%	$529.00K	-$46.89M	$0.00	$39.70M	(m)	(m)
2024-12-31	Reported	-$50.78M	(m)	(m)	(m)	-262.41%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	$56.03M*	$54.19M	$1.83M*	(m)	(m)	$592.00K*	$60.16M*	$168.00K	$40.54M	(m)	$0.00
2024-06-30	Reported	-$56.37M*	-$58.18M	$1.81M*	(m)	(m)	$1.03M*	-$44.48M*	$176.00K	$51.73M	(m)	$0.00
2024-03-31	Reported	-$51.91M	(m)	(m)	(m)	-570.18%	$1.46M	-$45.64M	$270.00K	$46.03M	(m)	(m)
2023-12-31	Reported	-$47.45M	(m)	(m)	(m)	-442.67%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$33.55M*	-$35.50M	$1.95M*	(m)	(m)	$499.00K*	-$35.25M*	$85.00K	$30.13M	(m)	(m)
2023-06-30	Reported	-$42.15M*	-$44.96M	$2.81M*	(m)	(m)	$286.00K*	-$2.09M*	$258.00K	$43.23M	(m)	(m)
2023-03-31	Reported	-$35.44M	(m)	(m)	(m)	-144.69%	$359.00K	-$12.83M	$113.00K	$45.87M	(m)	(m)
2022-12-31	Reported	$15.21M	(m)	(m)	(m)	20.81%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$22.11M*	-$24.95M	$2.84M*	(m)	(m)	$804.00K*	-$9.42M*	$3.01M	$48.19M	(m)	(m)
2022-06-30	Reported	-$38.93M*	-$41.81M	$2.88M*	(m)	(m)	$1.01M*	-$49.16M*	$180.00K	$51.74M	(m)	(m)
2022-03-31	Reported	-$63.73M	(m)	(m)	(m)	-574.05%	$1.42M	-$57.70M	$48.00K	$61.44M	(m)	(m)
2021-12-31	Reported	-$55.28M	(m)	(m)	(m)	-390.78%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$50.19M*	-$52.99M	$2.80M*	(m)	(m)	$2.13M*	-$14.79M*	$1.67M	$49.82M	(m)	(m)
2021-06-30	Reported	-$37.50M*	-$40.28M	$2.78M*	(m)	(m)	$2.07M*	-$45.69M*	$22.00K	$55.78M	(m)	(m)
2021-03-31	Reported	-$48.56M	(m)	(m)	(m)	-287.68%	$626.00K	-$29.04M	$17.00K	$53.12M	(m)	(m)
2020-12-31	Reported	$720,000.00	(m)	(m)	(m)	1.37%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$33.17M*	-$36.13M	$2.96M*	(m)	(m)	$499.00K*	-$25.68M*	$0.00	$44.66M	(m)	(m)
2020-06-30	Reported	-$44.28M*	-$47.31M	$3.03M*	(m)	(m)	$594.00K*	-$36.55M*	$0.00	$57.35M	(m)	(m)
2020-03-31	Reported	-$42.37M	(m)	(m)	(m)	-309.65%	$1.25M	-$44.14M	$0.00	$48.89M	(m)	(m)
2019-12-31	Reported	-$34.47M	(m)	(m)	(m)	-136.82%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$35.31M*	-$37.94M	$2.64M*	(m)	(m)	$780.00K*	-$17.39M*	(m)	$44.85M	(m)	(m)
2019-06-30	Reported	-$50.39M*	-$52.97M	$2.58M*	(m)	(m)	$587.00K*	-$48.84M*	(m)	$51.44M	(m)	(m)
2019-03-31	Reported	-$44.71M	(m)	(m)	(m)	-462.78%	$1.68M	-$30.00M	(m)	$47.06M	(m)	(m)
2018-12-31	Reported	-$37.79M	(m)	(m)	(m)	-239.24%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$32.28M*	-$35.00M	$2.73M*	(m)	(m)	$4.22M*	(m)	(m)	$46.22M	(m)	(m)
2018-06-30	Reported	-$43.11M*	-$44.31M	$1.20M*	(m)	(m)	$5.50M*	(m)	(m)	$52.01M	(m)	(m)
2018-03-31	Reported	-$48.87M	(m)	(m)	(m)	-1040.94%	$14.52M	(m)	(m)	$45.67M	(m)	(m)
2017-12-31	Reported	$106.31M	(m)	(m)	(m)	69.78%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$45.82M*	-$47.72M	$1.91M*	(m)	(m)	$9.85M*	(m)	(m)	$40.98M	(m)	(m)
2017-06-30	Reported	-$39.18M*	-$41.18M	$2.00M*	(m)	(m)	$7.30M*	(m)	(m)	$34.46M	(m)	(m)
2017-03-31	Reported	-$36.23M	(m)	(m)	(m)	-1763.02%	$1.49M	(m)	(m)	$32.80M	(m)	(m)
2016-12-31	Reported	-$33.26M	(m)	(m)	(m)	-651.47%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$32.19M*	-$34.27M	$2.08M*	(m)	(m)	$1.98M*	(m)	(m)	$30.30M	(m)	(m)
2016-06-30	Reported	$41.88M*	$40.09M	$1.79M*	(m)	(m)	$5.51M*	(m)	(m)	$33.34M	(m)	(m)
2016-03-31	Reported	-$28.86M	(m)	(m)	(m)	-1014.13%	$2.83M	(m)	(m)	$27.35M	(m)	(m)
2015-09-30	Reported	(m)	-$15.44M	(m)	(m)	(m)	$2.61M*	(m)	(m)	$24.10M	(m)	(m)
2015-06-30	Reported	(m)	-$21.29M	(m)	(m)	(m)	$2.81M*	(m)	(m)	$22.66M	(m)	(m)
2015-03-31	Reported	(m)	$45.13M	(m)	(m)	(m)	$997.00K	(m)	(m)	$21.46M	(m)	(m)
2014-09-30	Reported	(m)	-$3.93M	(m)	(m)	(m)	$672.00K*	(m)	(m)	$18.63M	(m)	(m)
2014-06-30	Reported	(m)	-$12.26M	(m)	(m)	(m)	$795.00K*	(m)	(m)	$17.34M	(m)	(m)
2014-03-31	Reported	(m)	-$3.11M	(m)	(m)	(m)	$447.00K	(m)	(m)	$14.57M	(m)	(m)
2013-12-31	Reported	-$2.84M	(m)	(m)	(m)	-19.05%	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	$7.47M	(m)	(m)	(m)	36.95%	$1.16M*	(m)	(m)	$11.09M	(m)	(m)
2013-06-30	Reported	(m)	-$254.00K	(m)	(m)	(m)	$450.91K*	(m)	(m)	$11.05M	(m)	(m)
2013-03-31	Reported	(m)	-$3.33M	(m)	(m)	(m)	$425.09K	(m)	(m)	$10.10M	(m)	(m)
2012-12-31	Reported	-$1.98M	(m)	(m)	(m)	-20.20%	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	$2.83M	(m)	(m)	(m)	17.63%	(m)	(m)	(m)	$11.97M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$65.67M	(m)	(m)	(m)	-43.93%	$1.91M	-$81.04M	$0.00	$147.17M	(m)	-$672.00K
2024-12-31	Reported	-$103.04M	(m)	(m)	(m)	-68.71%	$3.71M	-$68.37M	$847.00K	$177.19M	(m)	$944.00K
2023-12-31	Reported	-$158.6M	(m)	(m)	(m)	-269.96%	$1.76M	-$78.20M	$619.00K	$166.58M	(m)	$0.00
2022-12-31	Reported	-$109.55M	(m)	(m)	(m)	-72.10%	$3.62M	-$86.96M	$3.35M	$207.03M	(m)	$0.00
2021-12-31	Reported	-$191.54M	(m)	(m)	(m)	-247.31%	$6.20M	-$143.83M	$2.65M	$214.58M	(m)	$0.00
2020-12-31	Reported	-$119.1M	(m)	(m)	(m)	-113.56%	$5.91M	-$111.90M	$0.00	$193.20M	(m)	$0.00
2019-12-31	Reported	-$164.88M	(m)	(m)	(m)	-256.87%	$4.29M	-$134.27M	$0.00	$195.31M	(m)	$0.00
2018-12-31	Reported	-$162.05M	(m)	(m)	(m)	-269.53%	$24.95M	-$153.23M	(m)	$190.83M	(m)	$0.00
2017-12-31	Reported	-$14.92M	(m)	(m)	(m)	-9.46%	$29.40M	$14.40M	(m)	$147.23M	(m)	$0.00
2016-12-31	Reported	-$52.43M	(m)	(m)	(m)	-57.07%	$11.38M	(m)	(m)	$122.09M	(m)	$0.00
2015-12-31	Reported	-$17.32M	(m)	(m)	(m)	-17.17%	$9.20M	(m)	(m)	$98.27M	(m)	$0.00
2014-12-31	Reported	-$36.49M	(m)	(m)	(m)	-76.35%	$3.57M	(m)	(m)	$70.19M	(m)	$0.00
2013-12-31	Reported	$1.57M	(m)	(m)	(m)	2.70%	$2.96M	-$14.17M	(m)	$46.58M	(m)	$0.00
2012-12-31	Reported	$9.21M	(m)	(m)	(m)	14.42%	$940.00K	-$6.58M	(m)	$45.43M	(m)	$0.00
2011-12-31	Reported	$6.35M	(m)	(m)	(m)	11.10%	$500.21K	$6.76M	(m)	$41.09M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Cue Biopharma, Inc. (CUE)	United States	$0.243B	-1.01
Entrada Therapeutics, Inc. (TRDA)	United States	$0.243B	-1.73
Pyxis Oncology, Inc. (PYXS)	United States	$0.244B
Camp4 Therapeutics Corp (CAMP)	United States	$0.240B	-2.12
Lyell Immunopharma, Inc. (LYEL)	United States	$0.248B	-1.32
Sionna Therapeutics, Inc. (SION)	United States	$0.236B	-20.37
SIGA TECHNOLOGIES INC (SIGA)	United States	$0.234B	-93.33
Cartesian Therapeutics, Inc. (RNAC)	United States	$0.231B	-2.04
Keros Therapeutics, Inc. (KROS)	United States	$0.229B	-2.55
Akebia Therapeutics, Inc. (AKBA)	United States	$0.255B	-10.35